BR112022008020A2 - Métodos de tratamento de doenças e distúrbios relacionados a lsd1 com inibidores de lsd1 - Google Patents

Métodos de tratamento de doenças e distúrbios relacionados a lsd1 com inibidores de lsd1

Info

Publication number
BR112022008020A2
BR112022008020A2 BR112022008020A BR112022008020A BR112022008020A2 BR 112022008020 A2 BR112022008020 A2 BR 112022008020A2 BR 112022008020 A BR112022008020 A BR 112022008020A BR 112022008020 A BR112022008020 A BR 112022008020A BR 112022008020 A2 BR112022008020 A2 BR 112022008020A2
Authority
BR
Brazil
Prior art keywords
lsd1
fluoro
phenyl
disorders
related diseases
Prior art date
Application number
BR112022008020A
Other languages
English (en)
Inventor
Hitotsumachi Hiroko
MACHIDA Takumitsu
Yamada Masaki
Keer Harold
Oganesian Aram
Original Assignee
Taiho Pharmaceutical Co Ltd
Astex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd, Astex Pharmaceuticals Inc filed Critical Taiho Pharmaceutical Co Ltd
Publication of BR112022008020A2 publication Critical patent/BR112022008020A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE 4-[5-[(3S)-3-AMINOPIRROLIDINA-1-CARBONIL]-2-[2-FLUORO-4-(2-HIDRÓXI-2-METILPROPIL)FENIL]FENIL]-2-FLUORO-BENZONITRILA PARA TRATAR DOENÇAS E DISTÚRBIOS RELACIONADOS A LSD1 COM INIBIDORES DE LSD1, E COMPOSIÇÃO COMPREENDENDO O REFERIDO COMPOSTO. A presente invenção refere-se a um método de tratamento de uma doença ou distúrbio relacionado a LSD1 em um paciente em necessidade, o método compreendendo administrar uma quantidade eficaz de 4-[5-[(3S)-3-aminopirrolidino-1-carbonil]-2-[2-fluoro-4-(2-hidróxi-2-metil-propil)fenil]fenil]-2-fluoro-benzonitrila ou um sal do mesmo ao paciente em um programa de administração compreendendo dosagem diária por uma semana ou duas semanas, seguido por um período de descanso de uma semana.
BR112022008020A 2019-11-13 2020-11-13 Métodos de tratamento de doenças e distúrbios relacionados a lsd1 com inibidores de lsd1 BR112022008020A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962934923P 2019-11-13 2019-11-13
PCT/JP2020/042410 WO2021095840A1 (en) 2019-11-13 2020-11-13 METHODS OF TREATING LSD1-RELATED DISEASES and Disorders WITH LSD1 INHIBITORS

Publications (1)

Publication Number Publication Date
BR112022008020A2 true BR112022008020A2 (pt) 2022-07-12

Family

ID=75912767

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022009221A BR112022009221A2 (pt) 2019-11-13 2020-11-13 Sal de composto de terfenila
BR112022008020A BR112022008020A2 (pt) 2019-11-13 2020-11-13 Métodos de tratamento de doenças e distúrbios relacionados a lsd1 com inibidores de lsd1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112022009221A BR112022009221A2 (pt) 2019-11-13 2020-11-13 Sal de composto de terfenila

Country Status (18)

Country Link
US (2) US12419858B2 (pt)
EP (2) EP4058151B1 (pt)
JP (2) JP7492002B2 (pt)
KR (2) KR102825246B1 (pt)
CN (2) CN114828844A (pt)
AU (2) AU2020382379B2 (pt)
BR (2) BR112022009221A2 (pt)
CA (2) CA3157404A1 (pt)
DK (1) DK4058151T3 (pt)
ES (1) ES3034158T3 (pt)
FI (1) FI4058151T3 (pt)
HU (1) HUE072206T2 (pt)
MX (2) MX2022005811A (pt)
PH (2) PH12022551169A1 (pt)
PL (1) PL4058151T3 (pt)
PT (1) PT4058151T (pt)
TW (2) TWI874489B (pt)
WO (2) WO2021095835A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018276611B2 (en) 2017-05-31 2022-01-06 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
WO2021095835A1 (en) 2019-11-13 2021-05-20 Taiho Pharmaceutical Co., Ltd. Novel salt of terphenyl compound
US20250073232A1 (en) 2021-04-08 2025-03-06 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
EP4337638A1 (en) * 2021-05-11 2024-03-20 Astex Pharmaceuticals, Inc. Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile
US20250049757A1 (en) * 2021-09-30 2025-02-13 Taiho Pharmaceutical Co. Ltd. Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator
JP7788550B2 (ja) * 2021-10-26 2025-12-18 大鵬薬品工業株式会社 ターフェニル化合物の安息香酸塩の製造方法
US20250295660A1 (en) 2022-05-09 2025-09-25 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
EP4522136A1 (en) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
WO2024229073A1 (en) * 2023-05-02 2024-11-07 Otsuka Pharmaceutical Co., Ltd. Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801518D0 (sv) * 1988-04-22 1988-04-22 Astra Pharma Prod A novel process
US6225049B1 (en) 1992-06-17 2001-05-01 The United States Of America As Represented By The Department Of Health And Human Services Human insulinoma-associated cDNA
CA2469649C (en) 2001-12-13 2011-05-03 Natrogen Therapeutics, Inc. Derivatives of isoindigo, indigo and indirubin and use in treating cancer
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
EP1792622A1 (en) 2005-11-11 2007-06-06 GPC Biotech AG Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues
JP2011530511A (ja) 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
EP2350317A4 (en) 2008-10-20 2012-06-27 Univ Colorado Regents BIOLOGICAL MARKERS FOR PREDICTING THE ANTICIPATE RESPONSE TO INSULINARY GROWTH FACTOR 1 RECEPTOR KINASE INHIBITORS
US8367679B2 (en) 2008-12-09 2013-02-05 Merck Sharp & Dohme Corp. Biaryl carboxamides
EP2419177A1 (en) 2009-04-17 2012-02-22 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
BR112012027062B8 (pt) 2010-04-20 2021-05-25 Fond Ieo composto, processo para a preparação de um composto e usos do mesmo
BR112013002164B1 (pt) 2010-07-29 2021-11-09 Oryzon Genomics S.A. Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica
WO2012157647A1 (ja) 2011-05-16 2012-11-22 大鵬薬品工業株式会社 胃癌患者に対するテガフール・ギメラシル・オテラシルカリウム配合剤及びｅｇｆｒ阻害剤からなる化学療法の選択方法
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
CN104411316B (zh) * 2012-05-09 2018-05-01 坎泰克斯制药股份有限公司 骨髓抑制的治疗
US9834521B2 (en) 2013-03-15 2017-12-05 Ariad Pharmaceuticals, Inc. Choline kinase inhibitors
ES2734209T3 (es) 2013-08-06 2019-12-04 Imago Biosciences Inc Inhibidores de KDM1A para el tratamiento de enfermedades
US9266907B2 (en) 2013-09-05 2016-02-23 King Abdullah University Of Science And Technology Tunable rare-earth fcu-metal-organic frameworks
CA3161836A1 (en) 2013-12-11 2015-06-18 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
CN106061969B (zh) 2014-01-06 2019-10-29 阿尔戈么迪克斯有限公司 Trpa1调节剂
KR102400920B1 (ko) 2014-05-01 2022-05-20 셀젠 콴티셀 리서치, 인크. 리신 특이적 데메틸라제-1의 억제제
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
CA2958704A1 (en) 2014-08-25 2016-03-03 University Of Canberra Compositions for modulating cancer stem cells and uses therefor
AU2015311805B2 (en) 2014-09-05 2020-04-02 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
EP3285809B1 (en) 2015-04-20 2019-09-11 eFFECTOR Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
EP3381896B1 (en) * 2015-11-27 2023-01-18 Taiho Pharmaceutical Co., Ltd. Biphenyl compound or salt thereof
WO2018136961A1 (en) 2017-01-23 2018-07-26 Syros Pharmaceuticals Inc. METHODS OF TREATING PATIENTS WITH A RETINOIC ACID RECEPTOR-α AGONIST AND AN ANTI-CD38 ANTIBODY
TWI770925B (zh) * 2017-05-26 2022-07-11 日商大鵬藥品工業股份有限公司 使用有新穎聯苯化合物之抗腫瘤效果增強劑
KR102361918B1 (ko) 2017-05-26 2022-02-14 다이호야쿠힌고교 가부시키가이샤 신규 비페닐 화합물 또는 그의 염
AU2018276611B2 (en) * 2017-05-31 2022-01-06 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
KR20200020899A (ko) 2017-06-30 2020-02-26 셀진 코포레이션 2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 조성물 및 사용 방법
WO2019075327A1 (en) 2017-10-12 2019-04-18 Dana-Farber Cancer Institute, Inc. TREATMENT OF MERKEL CELL CARCINOMA
WO2019083971A1 (en) 2017-10-23 2019-05-02 Children's Medical Center Corporation METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY
AU2018377852B2 (en) 2017-11-29 2022-03-24 Epiaxis Therapeutics Pty Ltd Enhancing T-cell function and treating a T-cell dysfunctional disorder with a combination of an LSD inhibitor and a PD1 binding antagonist
KR20200105662A (ko) 2018-01-02 2020-09-08 셀진 코포레이션 2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 동위 이성질체
IL289453B2 (en) 2019-07-17 2026-03-01 Summit Oxford Ltd Process for preparing ridinilazole and its crystalline forms
WO2021095835A1 (en) 2019-11-13 2021-05-20 Taiho Pharmaceutical Co., Ltd. Novel salt of terphenyl compound
EP4114398A1 (en) 2020-03-06 2023-01-11 Celgene Quanticel Research, Inc. Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc

Also Published As

Publication number Publication date
TW202128617A (zh) 2021-08-01
KR20220113390A (ko) 2022-08-12
EP4058018A1 (en) 2022-09-21
US12419858B2 (en) 2025-09-23
KR102825246B1 (ko) 2025-06-25
EP4058151B1 (en) 2025-05-21
PL4058151T3 (pl) 2025-08-04
PH12022551137A1 (en) 2023-10-09
KR20220101145A (ko) 2022-07-19
TWI874490B (zh) 2025-03-01
CN114828844A (zh) 2022-07-29
EP4058151A4 (en) 2023-10-25
MX2022005812A (es) 2022-08-16
EP4058151A1 (en) 2022-09-21
CA3158442A1 (en) 2021-05-20
PT4058151T (pt) 2025-06-12
AU2020382214B2 (en) 2023-07-06
US20220411368A1 (en) 2022-12-29
AU2020382379B2 (en) 2024-03-28
AU2020382214A1 (en) 2022-04-21
CA3157404A1 (en) 2021-05-20
US20220387384A1 (en) 2022-12-08
CN114728899A (zh) 2022-07-08
JP2023501627A (ja) 2023-01-18
PH12022551169A1 (en) 2024-02-19
JP7379680B2 (ja) 2023-11-14
JP2022550374A (ja) 2022-12-01
WO2021095840A1 (en) 2021-05-20
MX2022005811A (es) 2022-06-08
ES3034158T3 (en) 2025-08-13
FI4058151T3 (fi) 2025-07-16
CN114728899B (zh) 2023-12-05
JP7492002B2 (ja) 2024-05-28
BR112022009221A2 (pt) 2022-07-26
WO2021095835A1 (en) 2021-05-20
DK4058151T3 (da) 2025-06-30
EP4058018A4 (en) 2023-06-21
TWI874489B (zh) 2025-03-01
AU2020382379A1 (en) 2022-05-05
TW202128616A (zh) 2021-08-01
HUE072206T2 (hu) 2025-10-28

Similar Documents

Publication Publication Date Title
BR112022008020A2 (pt) Métodos de tratamento de doenças e distúrbios relacionados a lsd1 com inibidores de lsd1
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
BR112014010803A2 (pt) método de tratamento
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112021021713A2 (pt) Método de tratamento de câncer ou inibição do crescimento de um tumor
BR112012021905A2 (pt) tratamento de nefrite lúpica usando laquinimod
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
BR112022000231A2 (pt) Novos métodos
BR112014015482A8 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
BR112012022064A2 (pt) tratamento de artrite lúpica usando laquinimod
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
BR112013020802A2 (pt) métodos e composições para tratar, reduzir ou impedir dano ao sistema nervoso de animais
BR112013018839A2 (pt) métodos e composições para o tratamento, a redução ou a prevenção de deterioração do sistema visual dos animais
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
BR112021018262A2 (pt) Tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidina
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
BR112015012497A2 (pt) combinações farmacêuticas
BR112015030664A2 (pt) combinação farmacêutica de um inibidor de pi3k e um agente desestabilizador de microtúbulos
PH12020500489A1 (en) Methods and compositions for treating chronic lung diseases
BR112021024835A2 (pt) Tratamento para sinuclenopatias
BR112017024073A2 (pt) métodos e composições para a inibição da via egf/egfr em combinação com inibidores de tirosina quinase

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]